<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676375</url>
  </required_header>
  <id_info>
    <org_study_id>0024</org_study_id>
    <nct_id>NCT02676375</nct_id>
  </id_info>
  <brief_title>Nicotine Receptor Density &amp; Response to Nicotine Patch: Pt 2 Extended Treatment</brief_title>
  <official_title>Nicotine Receptor Density &amp; Response to Nicotine Patch: Pt 2 Extended Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brentwood Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brentwood Biomedical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic&#xD;
      and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into&#xD;
      three arms of treatment for smoking cessation treatment, receiving either 1. Control:&#xD;
      &quot;standard therapy&quot; (n=15), including stepwise monotherapy of nicotine patch or bupropion&#xD;
      sustained release, 2. Extended treatment with combination bupropion, nicotine patch, and&#xD;
      nicotine lozenge for 6 months (n=15), or 3. Extended treatment with combination bupropion,&#xD;
      nicotine patch, and nicotine lozenge for 6 months with home visits (n=15) and phone calls to&#xD;
      the home or living facility. During all treatments, participants will receive weekly smoking&#xD;
      cessation group counseling, as is standard for smoking cessation treatment. At the time of&#xD;
      enrollment, participants will complete a one-study visit lead-in to complete baseline&#xD;
      assessments, psychological and medical evaluation, and comprehensive assessment of drug use&#xD;
      to determine study eligibility. Once determined to be eligible for the trial, participants&#xD;
      will be randomly assigned to one of the treatment arms using a randomization procedure. The&#xD;
      &quot;standard therapy&quot; treatment arm, or control group, will receive either nicotine patch taper&#xD;
      starting at 21 milligrams (mg) daily, nicotine lozenge as needed, and/or bupropion sustained&#xD;
      release at 150mg daily for 3 days, then 150 mg twice a day for a total of 12 weeks. The&#xD;
      extended therapy arm will start the nicotine patch at 21mg daily with as needed nicotine&#xD;
      lozenge for breakthrough cravings and initiation of bupropion sustained release at 150mg&#xD;
      daily for 3 days a week prior to starting nicotine replacement, then 150 mg twice daily for 6&#xD;
      months (as tolerated). The third arm will be identical to the second arm except for the added&#xD;
      home visit intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM)</measure>
    <time_frame>Measured week 0, 12, and 26</time_frame>
    <description>Weekly measurements of expired carbon monoxide in the units of parts per million (PPM) participants to evaluate abstinence from smoking (a value equal to or less than 3 PPM is considered abstinent).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Standard Monotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment as usual starting with one smoking cessation medication plus group therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Extended Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended treatment with multiple standard medications plus group therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Extended Treatment + Home Visits/Calls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended treatment with multiple standard medications plus group therapy plus home visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination Bupropion + NRTs</intervention_name>
    <arm_group_label>Combination Extended Treatment</arm_group_label>
    <arm_group_label>Combination Extended Treatment + Home Visits/Calls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Extended Treatment</intervention_name>
    <arm_group_label>Combination Extended Treatment</arm_group_label>
    <arm_group_label>Combination Extended Treatment + Home Visits/Calls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home Visits &amp; Calls</intervention_name>
    <arm_group_label>Combination Extended Treatment + Home Visits/Calls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monotherapy</intervention_name>
    <arm_group_label>Standard Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Veterans 21 years of age or older;&#xD;
&#xD;
          2. meet DSM-IV criteria for Schizophrenia or Schizoaffective disorder based on clinical&#xD;
             interview&#xD;
&#xD;
          3. meet DSM-IV criteria for nicotine dependence&#xD;
&#xD;
          4. must report smoking &gt;10 cigarettes daily and positive CO exhalation &gt;8ppm&#xD;
&#xD;
          5. seeking treatment for nicotine dependence;&#xD;
&#xD;
          6. willing and able to comply with study procedures;&#xD;
&#xD;
          7. willing and able to provide written informed consent;&#xD;
&#xD;
          8. if female, not pregnant or lactating and willing to use a medically reliable method of&#xD;
             birth control during the trial (e.g., birth control pills, Depo-Provera, and/or&#xD;
             condoms with spermicide).&#xD;
&#xD;
          9. Must be clinically stable (i.e., no inpatient hospitalizations for 3 months prior to&#xD;
             enrollment, no changes in medication in the four weeks prior to enrollment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. current or past history of cardiovascular disease including myocardial infarction,&#xD;
             acute coronary syndrome, angina pectoris, coronary artery disease, atrial&#xD;
             fibrillation/flutter, cor pulmonale, arrhythmia other than sinus tachycardia or sinus&#xD;
             bradycardia, or an EKG suggesting any of these;&#xD;
&#xD;
          2. systolic blood pressure greater than 160 or diastolic blood pressure greater than 100&#xD;
             (i.e. cutoffs for stage 2 hypertension)&#xD;
&#xD;
          3. a history of angioedema;&#xD;
&#xD;
          4. renal impairment (CrCl &lt; 50);&#xD;
&#xD;
          5. a current neurological disorder (e.g., organic brain disease, dementia) or a medical&#xD;
             history which would make study agent compliance difficult or which would compromise&#xD;
             informed consent;&#xD;
&#xD;
          6. a history of attempted suicide (lifetime) and/or suicidal ideation in the past year as&#xD;
             assessed by the C-SSRS;&#xD;
&#xD;
          7. currently on prescription medication that is contraindicated for use with bupropion;&#xD;
&#xD;
          8. currently using any form of nicotine replacement therapy;&#xD;
&#xD;
          9. current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by&#xD;
             DSM-IV within the past 6 months;&#xD;
&#xD;
         10. a history of sensitivity to bupropion or nicotine replacement;&#xD;
&#xD;
         11. any history of seizures or seizure disorder;&#xD;
&#xD;
         12. a history of serious head injury (ie, loss of consciousness longer than 1 hour, no&#xD;
             neuropsychological sequelae, no cognitive rehabilitation treatment post head injury&#xD;
&#xD;
         13. evidence of substance or alcohol dependence in the past six months; evidence of&#xD;
             substance or alcohol abuse in the past month;&#xD;
&#xD;
         14. sedatives or benzodiazepine use within 12 hours of testing based on urine toxicology&#xD;
             screening&#xD;
&#xD;
         15. history of mental retardation or developmental disability based on chart review&#xD;
&#xD;
         16. psychiatric hospitalization during study participation&#xD;
&#xD;
         17. history of an eating disorder&#xD;
&#xD;
         18. have a medical condition that could be made worse by treatment with nicotine,&#xD;
             including poorly controlled insulin dependent diabetes, uncontrolled hyperthyroidism,&#xD;
             pheochromocytoma, severe oropharyngeal, esophageal, or peptic ulcer disease, or severe&#xD;
             renal or hepatic impairment as determined via the baseline medical history and&#xD;
             physical exam&#xD;
&#xD;
         19. have an allergy to adhesive tape or latex or serious dermatologic disease (excluding&#xD;
             minor skin conditions such as mild eczema) due to potential for skin allergy to patch&#xD;
&#xD;
         20. have a known allergy to nicotine or any component of the nicotine patches&#xD;
&#xD;
         21. be pregnant or sexually active and not using reliable birth control methods&#xD;
             consistently (for females)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Los Angeles Veterans Affairs Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <results_first_submitted>July 10, 2018</results_first_submitted>
  <results_first_submitted_qc>July 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2019</results_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brentwood Biomedical Research Institute</investigator_affiliation>
    <investigator_full_name>Arthur Brody</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Monotherapy</title>
          <description>Treatment as usual starting with one smoking cessation medication plus group therapy.&#xD;
Monotherapy</description>
        </group>
        <group group_id="P2">
          <title>Combination Extended Treatment</title>
          <description>Extended treatment with multiple standard medications plus group therapy.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment</description>
        </group>
        <group group_id="P3">
          <title>Combination Extended Treatment + Home Visits/Calls</title>
          <description>Extended treatment with multiple standard medications plus group therapy plus home visits.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment&#xD;
Home Visits &amp; Calls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Monotherapy</title>
          <description>Treatment as usual starting with one smoking cessation medication plus group therapy.&#xD;
Monotherapy</description>
        </group>
        <group group_id="B2">
          <title>Combination Extended Treatment</title>
          <description>Extended treatment with multiple standard medications plus group therapy.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment</description>
        </group>
        <group group_id="B3">
          <title>Combination Extended Treatment + Home Visits/Calls</title>
          <description>Extended treatment with multiple standard medications plus group therapy plus home visits.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment&#xD;
Home Visits &amp; Calls</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="8"/>
                    <measurement group_id="B2" value="56" spread="10"/>
                    <measurement group_id="B3" value="56" spread="8"/>
                    <measurement group_id="B4" value="56" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM)</title>
        <description>Weekly measurements of expired carbon monoxide in the units of parts per million (PPM) participants to evaluate abstinence from smoking (a value equal to or less than 3 PPM is considered abstinent).</description>
        <time_frame>Measured week 0, 12, and 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Monotherapy</title>
            <description>Treatment as usual starting with one smoking cessation medication plus group therapy.&#xD;
Monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Combination Extended Treatment</title>
            <description>Extended treatment with multiple standard medications plus group therapy.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment</description>
          </group>
          <group group_id="O3">
            <title>Combination Extended Treatment + Home Visits/Calls</title>
            <description>Extended treatment with multiple standard medications plus group therapy plus home visits.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment&#xD;
Home Visits &amp; Calls</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM)</title>
          <description>Weekly measurements of expired carbon monoxide in the units of parts per million (PPM) participants to evaluate abstinence from smoking (a value equal to or less than 3 PPM is considered abstinent).</description>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="5.1"/>
                    <measurement group_id="O2" value="12.3" spread="9.9"/>
                    <measurement group_id="O3" value="12.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.9"/>
                    <measurement group_id="O2" value="5.6" spread="4.5"/>
                    <measurement group_id="O3" value="5.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="7.6"/>
                    <measurement group_id="O2" value="5.0" spread="3.3"/>
                    <measurement group_id="O3" value="5.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the 26 weeks the study was conducted.</time_frame>
      <desc>Due to the nature of the study, there was not a substantial risk for serious adverse events or mortality. Non serious adverse events were recorded non systematically.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Monotherapy</title>
          <description>Treatment as usual starting with one smoking cessation medication plus group therapy.&#xD;
Monotherapy</description>
        </group>
        <group group_id="E2">
          <title>Combination Extended Treatment</title>
          <description>Extended treatment with multiple standard medications plus group therapy.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment</description>
        </group>
        <group group_id="E3">
          <title>Combination Extended Treatment + Home Visits/Calls</title>
          <description>Extended treatment with multiple standard medications plus group therapy plus home visits.&#xD;
Combination Bupropion + NRTs&#xD;
Extended Treatment&#xD;
Home Visits &amp; Calls</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (with the patch)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Modest sample size lacked power to differentiate between the COMB-EXT groups with/without HV; no control group other than TAU; no motivation to quit rating scale; no biochemical (plasma, salivary, urine) measures taken to ensure abstinence</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Arthur Brody</name_or_title>
      <organization>Department of Psychiatry, University of California San Diego</organization>
      <phone>8585528585 ext 3775</phone>
      <email>abrody@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

